Comparison of neurochemical effects of the monoamine oxidase inhibitors phenelzine, moclobemide and brofaromine in the rat after short- and long-term administration

Journal of Affective Disorders

Volumn 58, Issue 2, 2000, Pages 135-144

  Urichuk, Liana J ^a   Allison, Karen ^a   Holt, Andrew ^a   Greenshaw, Andrew J ^a   Baker, Glen B ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

5 Hydroxytryptamine; Brofaromine; Moclobemide; Phenelzine; Tryptamine

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; BROFAROMINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PHENELZINE; PHENETHYLAMINE; SEROTONIN; TRITIUM; TRYPTAMINE;

ANIMAL EXPERIMENT; ARTICLE; BRAIN LEVEL; BRAIN METABOLISM; BRAIN TISSUE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DEPRESSION; GAS CHROMATOGRAPHY; LIGAND BINDING; MENTAL DISEASE; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RAT; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; URINE LEVEL;

ANIMALS; BRAIN; DOWN-REGULATION; LONG-TERM CARE; MALE; MOCLOBEMIDE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PHENELZINE; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN;

EID: 0034002948     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(99)00105-6     Document Type: Article

References (44)

1. Andree T.H., Clarke D.E. Characteristics and specificity of phenelzine and benserazide as inhibitors of benzylamine oxidase and monoamine oxidase. Biochem. Pharmacol. 31:1982;825-830.
2. Baker G.B., Coutts R.T., Bornstein R.A., Dewhurst W.G., Douglass A.B., MacDonald R.N. An electron-capture gas chromatographic method for analysis of urinary 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG). Res. Commun. Chem. Path. Pharmacol. 54:1986;141-144.
3. Baker G.B., Coutts R.T., Martin I.L. Analysis of amines in the central nervous system by gas chromatography with electron-capture detection. Prog. Neurobiol. 17:1981;1-24.
4. Baker G.B., Greenshaw A.J. Effects of long-term administration of antidepressants and neuroleptics on receptors in the central nervous system. Cell. Mol. Neurobiol. 9:1989;1-44.
5. Baker G.B., LeGatt D.F., Coutts R.T. Effects of acute and chronic administration of phenelzine on 2-phenylethylamine levels in rat brain. Proc. West. Pharmacol. Soc. 25:1982;417-420.
6. Baker G.B., Rao T.S., Coutts R.T. Electron-capture gas chromatographic analysis of β-phenylethylamine in tissues and body fluids using pentafluorobenzenesulfonyl chloride. J. Chromatogr. B. 381:1986;211-217.
7. Bakish D., Saxena B.M., Bowen R., D'Souza J. Reversible monoamine oxidase (MAO-A) inhibitors in panic disorder. Clin. Neuropharmacol. 16:1993;S77-S82.
8. Dyck L.E., Durden D.A., Boulton A.A. Formation of β-phenylethylamine from the antidepressant, β-phenylethylhydrazine. Biochem. Pharmacol. 34:1985;1925-1929.
9. 2-mediated behavior in the rat following noradrenergic or serotonergic denervation. J. Neural Trans. 84:1991;19-32.
10. Frances A., First M.B., Pincus H.A. DSM-IV Handbook. 1995;American Psychiatric Press, Washington, DC.
11. Garcia-Borreguero D., Lauer C.J., Ozdaglav A., Wiedemann K., Holsboer F., Krieg J.-C. Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A. Pharmacopsychiatry. 25:1992;261-264.
12. Geschke R., Körner J., Eggers H. Determination of the new monoamine oxidase inhibitor moclobemide and three of its metabolites in biological fluids by high-performance liquid chromatography. J. Chromatogr. 420:1987;111-120.
13. 2 and β-adrenergic receptor regulation in rat brain following chronic treatment with desipramine and fluoxetine alone and in combination. J. Neurochem. 62:1994;2262-2268.
14. 2 binding sites in rat cortex. J. Neural Trans. 41:1994;127-134.
15. 3H-tryptamine binding sites in the rat hippocampus and striatum. Neurochem. Res. 19:1994;5-8.
16. Holt A., Alton G., Seaman C.H., Loppnow G.R., Szpacenko A., Svendsen I., Palcic M.M. Identification of the quinone cofactor in mammalian semicarbazide-sensitive amine oxidase. Biochemistry. 37:1998;4946-4957.
17. Hyman S.E., Arana G.W., Rosenbaum J.F. Handbook of Psychiatric Drug Therapy. 1995;Little, Brown and Company, Boston, MA.
18. Juorio A.V., Paterson I.A. Tryptamine may couple dopaminergic and serotonergic transmission in the brain. Gen. Pharmacol. 5:1990;613-616.
19. Krishnan K.R.R. Monoamine oxidase inhibitors. Schatzberg A.F., Nemeroff C.B. American Psychiatric Press Textbook of Psychopharmacology. 2nd ed. 1998;APA Press, Washington, DC.
20. Lott M., Griest J.J., Jefferson J.W., Kobak K.A., Katzelnick D.J., Katz R.J., Schaettle S.C. Brofaromine for social phobia: a multicentre, placebo-controlled, double-blind study. J. Clin. Psychopharmacol. 17:1997;255-260.
21. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
22. Lyles G.A. Mammalian plasma and tissue-bound semicarbazide-sensitive amine oxidases: Biochemical, pharmacological and toxicological aspects. Int. J. Biochem. Cell. Biol. 28:1996;259-274.
23. Lyles G.A., Callingham B.A. Hydralazine is an irreversible inhibitor of the semicarbazide-sensitive, clorgyline-resistant amine oxidase in rat aorta homogenates. J. Pharm. Pharmacol. 34:1982;139-140.
24. Martin L.L., Neale R.F., Wood P.L. Down-regulation of tryptamine receptors following chronic administration of clorgyline. Brain Res. 419:1987;239-243.
25. McPherson G.A. Kinetic, EBDA, Ligand, Lowry. A Collection of Radioligand Binding Analysis Programs. 1987;Elsevier-Biosoft, UK.
26. Mousseau, D.D., 1991. Neurochemical studies on tryptamine. Ph.D. Thesis, University of Alberta.
27. Mousseau D.D. Tryptamine: A metabolite of tryptophan implicated in various neuropsychiatric disorders. Metab. Brain Dis. 8:1993;1-44.
28. 3H]dihydroalprenolol binding to rat cortical membranes. Cell. Mol. Neurobiol. 13:1993;3-13.
29. Nair N.P.V., Ahmed S.K., Ng Ying Kin N.M.K. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide. J. Psychiatr. Neurosci. 5:1993;214-225.
30. Paterson I.A., Juorio A.V., Boulton A.A. 2-Phenylethylamine: a modulator of catecholamine neurotransmission in the mammalian central nervous system. J. Neurochem. 55:1990;1827-1837.
31. Philips S.R., Boulton A.A. The effect of monoamine oxidase inhibitors on some arylalkylamines in rat striatum. J. Neurochem. 33:1979;159-167.
32. Preskorn S.H. Pharmacokinetics of antidepressants: Why and how are they relevant to treatment? J. Clin. Psychiatr. 54:1993;14-34.
33. Priest R.G. Moclobemide and the reversible inhibitors of monoamine oxidase antidepressants. Acta Psychiatr. Scand. 360:1990;39-41.
34. Priest R.G., Gimbett R., Roberts M., Steinert J. Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders. Acta Psychiatr. Scand. 91:1995;40-43.
35. Quitkin F.M., Harrison W., Stewart J.W., McGrath P.J., Tricamo E. Response to phenelzine and imipramine in placebo nonresponders with atypical depression: a new application of the crossover design. Arch. Gen. Psychiatr. 48:1991;319-323.
36. Schiwy W., Heath W.R., Delini-Stula A. Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor, brofaromine. Results of dose-finding trials on depressed patients. J. Neural Trans. 28:1989;33-44.
37. Sherry-McKenna R.L., Baker G.B., Mousseau D.D., Coutts R.T., Dewhurst W.G. 4-Methoxytranylcypromine, a monoamine oxidase inhibitor: effects on biogenic amines in rat brain following chronic administration. Biol. Psychiatr. 31:1992;881-888.
38. 2A receptors without affecting benzodiazepine binding sites in rat brain. Cell. Mol. Neurobiol. 15:1995;361-370.
39. Verhoeven W. Brofaromine in endogenous depression. Prog. Neuropsycho-Pharmacol. Biol. Psychiatr. 18:1994;235-241.
40. Volz H.P., Faltrus F., Magyar I., Möller H.J. Brofaromine in treatment-resistant depressed patients - a comparative trial versus tranylcypromine. J. Affect. Disord. 30:1994;209-217.
41. Volz H.P., Gleiter C.H., Möller H.J. Brofaromine versus imipramine in in-patients with major depression - a controlled trial. J. Affect. Disord. 44:1997;91-99.
42. Waldmeier P.C., Amrein R., Schmid-Burgk W. Pharmacology and pharmacokinetics of brofaromine and moclobemide in animals and humans. Kennedy S.H. Clinical Advances in Monoamine Oxidase Inhibitors. 1994;33-60 American Psychiatric Press, Washington, DC.
43. Waldmeier P.C., Glatt A., Jaekel J., Bittiger H. Brofaromine: a monoamine oxidase-A and serotonin reuptake inhibitor. Clin. Neuropharmacol. 16:1993;19-24.
44. 3H] tryptamine binding sites in rat brain, distribution and pharmacology. Arch. Int. Pharmacodyn. 268:1984;194-201.